Concourse Financial Group Securities, Inc. Relay Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$6.23 - $9.51 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$5.9 - $8.02 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$7.5 - $12.07 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$6.01 - $11.48 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$8.24 - $12.97 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$8.24 - $12.97 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$9.99 - $18.27 $0 - $0
Q1 2023 May 15, 2023	BUY	$15.0 - $22.76 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$14.16 - $24.02 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$18.07 - $31.37 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$13.31 - $34.88 $0 - $0
Q1 2022 May 09, 2022	BUY	$20.26 - $32.36 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$26.0 - $37.03 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$29.75 - $37.99 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$27.5 - $38.19 $0 - $0
Q1 2021 May 13, 2021	BUY	$32.52 - $61.53 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$35.51 - $54.03 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$32.81 - $45.1 $0 - $0

Others Institutions Holding RLAY

# of Institutions

204

Shares Held

156M

Call Options Held

207K

Put Options Held

40K

Sb Investment Advisers (Uk) LTD London, X0

27.9M
Shares

$133 Million
1.63% of portfolio
Vanguard Group Inc Valley Forge, PA

14.5M
Shares

$68.7 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.5M
Shares

$50.1 Million
0.0% of portfolio
Casdin Capital, LLC New York, NY

9.25M
Shares

$43.9 Million
5.09% of portfolio
Bellevue Group Ag Kuesnacht, V8

7.38M
Shares

$35 Million
0.88% of portfolio

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $571M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account